JP2014504613A - ポリ硫酸化多糖類を用いる骨髄浮腫(edema(oedema))の治療 - Google Patents
ポリ硫酸化多糖類を用いる骨髄浮腫(edema(oedema))の治療 Download PDFInfo
- Publication number
- JP2014504613A JP2014504613A JP2013552065A JP2013552065A JP2014504613A JP 2014504613 A JP2014504613 A JP 2014504613A JP 2013552065 A JP2013552065 A JP 2013552065A JP 2013552065 A JP2013552065 A JP 2013552065A JP 2014504613 A JP2014504613 A JP 2014504613A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- polysulfate
- bone marrow
- polysulfated
- pentosan polysulfate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010051763 Bone marrow oedema Diseases 0.000 title claims abstract description 72
- 150000004676 glycans Chemical class 0.000 title claims abstract description 47
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 47
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 47
- 238000011282 treatment Methods 0.000 title claims abstract description 26
- 206010030113 Oedema Diseases 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 37
- 241000124008 Mammalia Species 0.000 claims abstract description 32
- -1 salts thereof Chemical class 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 229940043138 pentosan polysulfate Drugs 0.000 claims description 93
- 239000000203 mixture Substances 0.000 claims description 32
- 239000007924 injection Substances 0.000 claims description 22
- 238000002347 injection Methods 0.000 claims description 22
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 20
- 229960002897 heparin Drugs 0.000 claims description 20
- 229920000669 heparin Polymers 0.000 claims description 20
- 229920001661 Chitosan Polymers 0.000 claims description 16
- 229920002567 Chondroitin Polymers 0.000 claims description 15
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 claims description 15
- 239000003055 low molecular weight heparin Substances 0.000 claims description 14
- 229940127215 low-molecular weight heparin Drugs 0.000 claims description 14
- 238000007920 subcutaneous administration Methods 0.000 claims description 13
- 238000007918 intramuscular administration Methods 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- NBTMNFYXJYCQHQ-UHFFFAOYSA-N (2,3,4,5,6-pentasulfooxycyclohexyl) hydrogen sulfate Chemical compound OS(=O)(=O)OC1C(OS(O)(=O)=O)C(OS(O)(=O)=O)C(OS(O)(=O)=O)C(OS(O)(=O)=O)C1OS(O)(=O)=O NBTMNFYXJYCQHQ-UHFFFAOYSA-N 0.000 claims description 9
- OEANUJAFZLQYOD-CXAZCLJRSA-N (2r,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-5-acetamido-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](OC)O[C@H](CO)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](OC)[C@H](C(O)=O)O1 OEANUJAFZLQYOD-CXAZCLJRSA-N 0.000 claims description 9
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical class C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 claims description 9
- 229920000045 Dermatan sulfate Polymers 0.000 claims description 9
- 229920002971 Heparan sulfate Polymers 0.000 claims description 9
- 150000001408 amides Chemical class 0.000 claims description 9
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- 229960000633 dextran sulfate Drugs 0.000 claims description 9
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Polymers O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 9
- WEPNHBQBLCNOBB-FZJVNAOYSA-N sucrose octasulfate Chemical compound OS(=O)(=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@H](COS(=O)(=O)O)O[C@]1(COS(O)(=O)=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](COS(O)(=O)=O)O1 WEPNHBQBLCNOBB-FZJVNAOYSA-N 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 8
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- 159000000007 calcium salts Chemical class 0.000 claims description 6
- 159000000003 magnesium salts Chemical class 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 239000000829 suppository Substances 0.000 claims description 6
- 238000011269 treatment regimen Methods 0.000 claims description 5
- 241000282414 Homo sapiens Species 0.000 claims description 4
- 159000000000 sodium salts Chemical class 0.000 claims description 4
- 238000002595 magnetic resonance imaging Methods 0.000 description 31
- 208000002193 Pain Diseases 0.000 description 24
- 230000003902 lesion Effects 0.000 description 18
- 210000001185 bone marrow Anatomy 0.000 description 13
- 210000000988 bone and bone Anatomy 0.000 description 12
- 201000008482 osteoarthritis Diseases 0.000 description 11
- 238000001990 intravenous administration Methods 0.000 description 10
- 230000006378 damage Effects 0.000 description 7
- 210000005065 subchondral bone plate Anatomy 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 208000006820 Arthralgia Diseases 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 208000034656 Contusions Diseases 0.000 description 5
- 239000003708 ampul Substances 0.000 description 5
- 206010018735 Groin pain Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 210000001188 articular cartilage Anatomy 0.000 description 4
- 210000000845 cartilage Anatomy 0.000 description 4
- 208000031513 cyst Diseases 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 210000003127 knee Anatomy 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 208000017234 Bone cyst Diseases 0.000 description 3
- 206010011732 Cyst Diseases 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 210000001264 anterior cruciate ligament Anatomy 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 210000000629 knee joint Anatomy 0.000 description 3
- 208000024765 knee pain Diseases 0.000 description 3
- 210000003041 ligament Anatomy 0.000 description 3
- 230000000399 orthopedic effect Effects 0.000 description 3
- 229940071643 prefilled syringe Drugs 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 206010066251 Bone contusion Diseases 0.000 description 2
- 206010064269 Bone marrow oedema syndrome Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000777300 Congiopodidae Species 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 206010060820 Joint injury Diseases 0.000 description 2
- 208000023178 Musculoskeletal disease Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 208000013201 Stress fracture Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 210000000544 articulatio talocruralis Anatomy 0.000 description 2
- 208000034526 bruise Diseases 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000004439 collateral ligament Anatomy 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000005786 degenerative changes Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000000968 fibrocartilage Anatomy 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 208000030175 lameness Diseases 0.000 description 2
- 210000002346 musculoskeletal system Anatomy 0.000 description 2
- 238000000554 physical therapy Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- QUCDWLYKDRVKMI-UHFFFAOYSA-M sodium;3,4-dimethylbenzenesulfonate Chemical class [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1C QUCDWLYKDRVKMI-UHFFFAOYSA-M 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000002303 tibia Anatomy 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- GRYSXUXXBDSYRT-WOUKDFQISA-N (2r,3r,4r,5r)-2-(hydroxymethyl)-4-methoxy-5-[6-(methylamino)purin-9-yl]oxolan-3-ol Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1OC GRYSXUXXBDSYRT-WOUKDFQISA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010063057 Cystitis noninfective Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 208000022120 Jeavons syndrome Diseases 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 229920000439 Sulodexide Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000469816 Varus Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000001567 anti-fibrinolytic effect Effects 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 230000008414 cartilage metabolism Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 210000003108 foot joint Anatomy 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940127227 gastrointestinal drug Drugs 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000003225 hyperhomocysteinemia Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940025708 injectable product Drugs 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000000236 metacarpal bone Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 210000003049 pelvic bone Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229960003491 sulodexide Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 210000003857 wrist joint Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
骨への潜在的損傷は、骨打撲または骨挫傷と呼ばれることが多く、また、X線写真で、または磁気共鳴画像法(MRI)により、骨髄嚢胞または骨髄浮腫として容易に示される。これらの病変は、MRIのT1強調画像上では、信号強度の低下として、T2強調画像上では、信号強度の上昇として現れる。そのMRI信号は、骨髄内での骨梁の微小骨折および崩壊領域中の組織液の濃度の上昇から生じると考えられている。これらの病変は、骨への直接的な打撃、互いに衝突し合う隣接する骨の圧縮力、または靭帯や腱の骨への付着部においてなどの引き抜き損傷の間に生じる牽引力の結果である可能性がある。他の状況では、あるスポーツ活動で生じ得るような過度の回転/せん断/伸長ストレスが、恥骨結合において頻繁に見られ、「鼠径部痛」と診断されるような、組織内での浮腫性病変を発生させ得る。
A.哺乳類における骨髄浮腫を治療するための方法であって、その塩を含めたポリ硫酸化多糖類の有効量を、そうした治療を必要とする哺乳類に投与するステップを含む方法。
(実施例)
Claims (12)
- 哺乳類における骨髄浮腫を治療するための方法であって、その塩を含めたポリ硫酸化多糖類の有効量を、そうした治療を必要とする哺乳類に投与することを含む方法。
- 哺乳類における骨髄浮腫を治療するための、その塩を含めたポリ硫酸化多糖類の有効量、および薬学的に許容される担体を含む組成物。
- 骨髄浮腫を治療するための医薬の製造における、その塩を含めたポリ硫酸化多糖類の使用。
- ポリ硫酸化多糖類が、高分子量ヘパリン、低分子量ヘパリン、ヘパラン硫酸、ペントサンポリ硫酸、コンドロイチンポリ硫酸、キトサンポリ硫酸、デルマタンポリ硫酸スロデキシド、デキストラン硫酸、ポリ硫酸化イヌリン、硫酸化ラクトビオン酸アミド、硫酸化ビス−アルドン酸アミド、スクロース八硫酸、フコイダン−1、フコイダン−2、硫酸化β−シクロデキストリン、硫酸化γ−シクロデキストリンおよび小さい硫酸化化合物(イノシトール六硫酸を含むがこれに限定されない)からなる群から選択される、請求項1に記載の方法、請求項2に記載の組成物、または請求項3に記載の使用。
- ポリ硫酸化多糖類が、高分子量ヘパリン、低分子量ヘパリン、ペントサンポリ硫酸、コンドロイチンポリ硫酸およびキトサンポリ硫酸からなる群から選択される、請求項4に記載の方法、組成物、または使用。
- ポリ硫酸化多糖類が、ペントサンポリ硫酸、ペントサンポリ硫酸のナトリウム塩(NaPPS)、ペントサンポリ硫酸のマグネシウム塩(MgPPS)、およびペントサンポリ硫酸のカルシウム塩(CaPPS)からなる群から選択される、請求項5に記載の方法、組成物、または使用。
- ポリ硫酸化多糖類が、ペントサンポリ硫酸ナトリウムである、請求項6に記載の方法、組成物、または使用。
- 治療が、筋肉内(IM)もしくは皮下(SC)経路による注射で、静脈内的に(IV)、関節内的に(IA)、関節周囲的に、局所的に、座薬を介してまたは経口的に投与することによるものである、請求項1から7のいずれか一項に記載の方法、組成物、または使用。
- 治療が、注射剤を投与することによるものである、請求項8に記載の方法、組成物、または使用。
- 有効量が、1用量あたり、哺乳類1kgにつき約1〜2mgである、請求項1から9のいずれか一項に記載の方法、組成物、または使用。
- ヒトへの投与が、1日1回または週3回の治療レジメンで投薬することによるものである、請求項10に記載の方法、組成物、または使用。
- 治療レジメンで投与されるポリ硫酸化多糖類の合計用量が、約200〜2000mgである、請求項11に記載の方法、組成物、または使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2011900325 | 2011-02-02 | ||
AU2011900325A AU2011900325A0 (en) | 2011-02-02 | Treatment of bone marrow edema (oedema) with polysulfated polysaccharides | |
PCT/AU2012/000091 WO2012103588A1 (en) | 2011-02-02 | 2012-02-02 | Treatment of bone marrow edema (oedema) with polysulfated polysaccharides |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014504613A true JP2014504613A (ja) | 2014-02-24 |
JP2014504613A5 JP2014504613A5 (ja) | 2015-03-19 |
JP5883458B2 JP5883458B2 (ja) | 2016-03-15 |
Family
ID=46602012
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013552065A Active JP5883458B2 (ja) | 2011-02-02 | 2012-02-02 | ポリ硫酸化多糖類を用いる骨髄浮腫(edema(oedema))の治療 |
Country Status (15)
Country | Link |
---|---|
US (6) | US9101650B2 (ja) |
EP (1) | EP2670412B1 (ja) |
JP (1) | JP5883458B2 (ja) |
KR (1) | KR101840079B1 (ja) |
CN (1) | CN103415293B (ja) |
AU (1) | AU2012212398B2 (ja) |
CA (1) | CA2826166C (ja) |
DK (1) | DK2670412T3 (ja) |
ES (1) | ES2664611T3 (ja) |
MY (1) | MY164728A (ja) |
NO (1) | NO2670412T3 (ja) |
PT (1) | PT2670412T (ja) |
SG (1) | SG192238A1 (ja) |
TW (1) | TWI520740B (ja) |
WO (1) | WO2012103588A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020530030A (ja) * | 2017-08-04 | 2020-10-15 | パラダイム バイオファーマシューティカルズ リミテッド | ポリ硫酸化多糖類を用いた骨髄病態の治療 |
JP2021514988A (ja) * | 2018-02-28 | 2021-06-17 | パラダイム バイオファーマシューティカルズ リミテッド | ポリ硫酸化多糖類を用いた術後関節痛の処置 |
JP2022512662A (ja) * | 2018-10-10 | 2022-02-07 | パラダイム バイオファーマシューティカルズ リミテッド | ポリ硫酸化多糖を用いた疼痛の治療 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10098906B2 (en) * | 2013-10-22 | 2018-10-16 | Cell Receptor AG | Modulation of the physical interaction between platelets and the cell surface effecting cell proliferation |
WO2019157560A1 (en) | 2018-02-16 | 2019-08-22 | Proteobioactives Pty Limited | Methods and compositions for the treatment of pain and/or inflammation |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020128548A1 (en) * | 2000-12-18 | 2002-09-12 | Stevens Randall Marion | Bone marrow edema as predictive of susceptibility to developing progressive osteoarthritis |
JP2004513185A (ja) * | 2000-11-21 | 2004-04-30 | アースロファーム プロプライエタリー リミテッド | 骨粗鬆症の治療 |
JP2005536476A (ja) * | 2002-06-06 | 2005-12-02 | シエーリング アクチエンゲゼルシャフト | 骨髄浮腫に関連する病気治療用医薬製剤の製造のための経口用プロスタサイクリン誘導体の使用 |
WO2009070842A1 (en) * | 2007-12-04 | 2009-06-11 | Proteobioactives Pty Ltd | Protection of progenitor cells and regulation of their differentiation |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5668116A (en) | 1987-03-19 | 1997-09-16 | Anthropharm Pty. Limited | Anti-inflammatory compounds and compositions |
-
2012
- 2012-02-01 TW TW101103252A patent/TWI520740B/zh active
- 2012-02-02 JP JP2013552065A patent/JP5883458B2/ja active Active
- 2012-02-02 US US13/983,406 patent/US9101650B2/en active Active
- 2012-02-02 CN CN201280007433.9A patent/CN103415293B/zh active Active
- 2012-02-02 WO PCT/AU2012/000091 patent/WO2012103588A1/en active Application Filing
- 2012-02-02 DK DK12741560.2T patent/DK2670412T3/en active
- 2012-02-02 PT PT127415602T patent/PT2670412T/pt unknown
- 2012-02-02 EP EP12741560.2A patent/EP2670412B1/en active Active
- 2012-02-02 KR KR1020137022985A patent/KR101840079B1/ko active IP Right Grant
- 2012-02-02 AU AU2012212398A patent/AU2012212398B2/en active Active
- 2012-02-02 NO NO12741560A patent/NO2670412T3/no unknown
- 2012-02-02 CA CA2826166A patent/CA2826166C/en active Active
- 2012-02-02 MY MYPI2013701355A patent/MY164728A/en unknown
- 2012-02-02 SG SG2013058268A patent/SG192238A1/en unknown
- 2012-02-02 ES ES12741560.2T patent/ES2664611T3/es active Active
-
2015
- 2015-07-02 US US14/790,476 patent/US9861657B2/en active Active
-
2017
- 2017-09-29 US US15/720,884 patent/US10610542B2/en active Active
-
2020
- 2020-02-25 US US16/800,245 patent/US11406660B2/en active Active
-
2022
- 2022-07-05 US US17/857,420 patent/US20220362284A1/en not_active Abandoned
-
2023
- 2023-11-21 US US18/515,823 patent/US20240156858A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004513185A (ja) * | 2000-11-21 | 2004-04-30 | アースロファーム プロプライエタリー リミテッド | 骨粗鬆症の治療 |
US20020128548A1 (en) * | 2000-12-18 | 2002-09-12 | Stevens Randall Marion | Bone marrow edema as predictive of susceptibility to developing progressive osteoarthritis |
JP2005536476A (ja) * | 2002-06-06 | 2005-12-02 | シエーリング アクチエンゲゼルシャフト | 骨髄浮腫に関連する病気治療用医薬製剤の製造のための経口用プロスタサイクリン誘導体の使用 |
WO2009070842A1 (en) * | 2007-12-04 | 2009-06-11 | Proteobioactives Pty Ltd | Protection of progenitor cells and regulation of their differentiation |
Non-Patent Citations (3)
Title |
---|
JPN6015040124; Nephrology Dialysis Transplantation Vol.15, No.11, 2000, p.1859-1864 * |
JPN6015040125; Arthritis & Rheumatism Vol.46, No.7, 2002, p.1813-1819 * |
JPN6015040130; Current Therapeutic Research Vol.66, No.6, 2005, p.552-571 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020530030A (ja) * | 2017-08-04 | 2020-10-15 | パラダイム バイオファーマシューティカルズ リミテッド | ポリ硫酸化多糖類を用いた骨髄病態の治療 |
JP2021514988A (ja) * | 2018-02-28 | 2021-06-17 | パラダイム バイオファーマシューティカルズ リミテッド | ポリ硫酸化多糖類を用いた術後関節痛の処置 |
JP7391858B2 (ja) | 2018-02-28 | 2023-12-05 | パラダイム バイオファーマシューティカルズ リミテッド | ポリ硫酸化多糖類を用いた術後関節痛の処置 |
JP2022512662A (ja) * | 2018-10-10 | 2022-02-07 | パラダイム バイオファーマシューティカルズ リミテッド | ポリ硫酸化多糖を用いた疼痛の治療 |
Also Published As
Publication number | Publication date |
---|---|
CA2826166A1 (en) | 2012-08-09 |
MY164728A (en) | 2018-01-30 |
EP2670412A4 (en) | 2015-07-08 |
US20150297633A1 (en) | 2015-10-22 |
ES2664611T3 (es) | 2018-04-20 |
EP2670412A1 (en) | 2013-12-11 |
PT2670412T (pt) | 2018-03-20 |
US9101650B2 (en) | 2015-08-11 |
NO2670412T3 (ja) | 2018-06-02 |
CN103415293B (zh) | 2016-08-10 |
SG192238A1 (en) | 2013-09-30 |
US20220362284A1 (en) | 2022-11-17 |
DK2670412T3 (en) | 2018-03-12 |
KR101840079B1 (ko) | 2018-03-19 |
KR20140012655A (ko) | 2014-02-03 |
EP2670412B1 (en) | 2018-01-03 |
US9861657B2 (en) | 2018-01-09 |
US20140024614A1 (en) | 2014-01-23 |
WO2012103588A1 (en) | 2012-08-09 |
US11406660B2 (en) | 2022-08-09 |
JP5883458B2 (ja) | 2016-03-15 |
TWI520740B (zh) | 2016-02-11 |
CA2826166C (en) | 2017-05-09 |
TW201309307A (zh) | 2013-03-01 |
US10610542B2 (en) | 2020-04-07 |
AU2012212398A1 (en) | 2013-09-19 |
US20210015849A1 (en) | 2021-01-21 |
AU2012212398B2 (en) | 2014-06-05 |
CN103415293A (zh) | 2013-11-27 |
US20180021369A1 (en) | 2018-01-25 |
US20240156858A1 (en) | 2024-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11406660B2 (en) | Treatment of bone marrow edema (OEDEMA) with polysulfated polysaccharides | |
KR20090051100A (ko) | Fgf-18 로 연골 질환의 치료 | |
Herman et al. | 41 Complications of tibial eminence and diaphyseal fractures in children: prevention and treatment | |
van Roermund et al. | Joint distraction in the treatment of ankle osteoarthritis | |
JP7391858B2 (ja) | ポリ硫酸化多糖類を用いた術後関節痛の処置 | |
Alderman | Prolotherapy for knee pain | |
Satheesh et al. | A prospective study of surgical management of Schatzker Type V (Bicondylar) & Type Vi tibial plateau fracture by dual plating | |
Thirunthaiyan et al. | Efficacy of intra-articular corticosteroid and hyaluronic acid injections in preventing progression of early osteoarthritis of the knee in Indian population–A single centre prospective study with a follow-up of 18 months | |
Zhang et al. | Single-incision Non-weight-bearing Area Autologous Osteochondral Transplantation for the Treatment of Osteochondral Lesions of the Talus | |
Acharya et al. | Viscosupplements for Knee Osteoarthritis | |
Strauss et al. | Identifying and managing ankle fractures in older patients | |
Chen et al. | 7KH, PSURYHPHQW RI 3DLQ 6\PSWRPV DQG $ FWLYLWLHV RI'DLO\/LYLQJ LQ 3HRSOH ZLWK. QHH 2VWHRDUWKULWLV $ IWHU, QWUD DUWLFXODU+\DOXURQLF $ FLG, QMHFWLRQ | |
Rosario Saccomanno et al. | Monthly Archives: December 2020 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150130 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150130 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151013 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151228 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160126 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160205 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5883458 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |